Voyager Therapeutics, a biotechnology company dedicated to advancing gene therapies for severe neurological diseases, faces competition from a range of companies within the broader biopharmaceutical and therapeutics sectors. These competitors operate across various therapeutic areas and technology platforms, vying for market share, investment, and talent.
Key Competitors of Voyager Therapeutics
The primary competitors for Voyager Therapeutics include a diverse group of companies. While some may directly compete in gene therapy or neurological disorders, others are part of the wider biotech landscape, offering alternative treatments or vying for the same patient populations and research funding.
Here is a list of the main competitors:
| Company Name | Stock Ticker |
|---|---|
| Ocular Therapeutix | OCUL |
| Mesoblast | MESO |
| Travere Therapeutics | TVTX |
| Intellia Therapeutics | NTLA |
| Praxis Precision Medicines | PRAX |
| Arvinas | ARVN |
| Day One Biopharmaceuticals | DAWN |
| Ardelyx | ARDX |
| Spyre Therapeutics | SYRE |
| ARS Pharmaceuticals | SPRY |
These companies represent various segments of the biopharmaceutical industry, with some focusing on specific diseases, others on particular drug modalities like gene editing or small molecules, and still others on broader therapeutic areas. Their competition stems from their potential to develop therapies that could serve similar patient needs, attract similar investment, or recruit from the same pool of scientific talent. The competitive landscape for Voyager Therapeutics is dynamic, encompassing both direct rivals in gene therapy and indirect competitors from the wider pharmaceutical and biotech sectors.
